SynAct Pharma AB (SYNACT) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.170x

Based on the latest financial reports, SynAct Pharma AB (SYNACT) has a cash flow conversion efficiency ratio of -0.170x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-32.95 Million ≈ $-3.55 Million USD) by net assets (Skr193.75 Million ≈ $20.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SYNACT company net worth for the company's overall valuation and market capitalisation.

SynAct Pharma AB - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how SynAct Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

SynAct Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of SynAct Pharma AB ranked by their cash flow conversion efficiency. See SynAct Pharma AB (SYNACT) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
KOMPLETT ASA NK -40 F:GJ60	0.129x
Goltas Goller Bolgesi Cimento Sanayi ve Ticaret AS IS:GOLTS	0.042x
Tamil Nadu Newsprint & Papers Limited NSE:TNPL	-0.022x
Mobile Infrastructure Corporation NYSE MKT:BEEP	0.007x
Tung Ho Textile Co Ltd TW:1414	0.013x
Merkur PrivatBank KgaA XETRA:MBK	N/A
Patriot National Bancorp Inc NASDAQ:PNBK	-0.063x
Schloss Wachenheim AG F:SWA	-0.008x

Annual Cash Flow Conversion Efficiency for SynAct Pharma AB (2016–2025)

The table below shows the annual cash flow conversion efficiency of SynAct Pharma AB from 2016 to 2025. View SynAct Pharma AB share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr170.29 Million ≈ $18.33 Million	Skr-97.33 Million ≈ $-10.47 Million	-0.572x	-37.23%
2024-12-31	Skr214.17 Million ≈ $23.05 Million	Skr-89.20 Million ≈ $-9.60 Million	-0.416x	+26.75%
2023-12-31	Skr176.19 Million ≈ $18.96 Million	Skr-100.18 Million ≈ $-10.78 Million	-0.569x	+38.81%
2022-12-31	Skr126.52 Million ≈ $13.62 Million	Skr-117.56 Million ≈ $-12.65 Million	-0.929x	+70.17%
2021-12-31	Skr20.87 Million ≈ $2.25 Million	Skr-65.00 Million ≈ $-6.99 Million	-3.115x	-48.68%
2020-12-31	Skr15.87 Million ≈ $1.71 Million	Skr-33.24 Million ≈ $-3.58 Million	-2.095x	-75.44%
2019-12-31	Skr13.50 Million ≈ $1.45 Million	Skr-16.12 Million ≈ $-1.74 Million	-1.194x	+49.15%
2018-12-31	Skr10.31 Million ≈ $1.11 Million	Skr-24.21 Million ≈ $-2.61 Million	-2.348x	-76.25%
2017-12-31	Skr12.91 Million ≈ $1.39 Million	Skr-17.20 Million ≈ $-1.85 Million	-1.332x	-144.84%
2016-12-31	Skr27.08 Million ≈ $2.91 Million	Skr-14.73 Million ≈ $-1.59 Million	-0.544x	--

About SynAct Pharma AB

ST:SYNACT Sweden Biotechnology

Market Cap

$108.23 Million

Skr1.01 Billion SEK

Market Cap Rank

#19006 Global

#330 in Sweden

Share Price

Skr17.96

Change (1 day)

-1.21%

52-Week Range

Skr10.66 - Skr24.95

All Time High

Skr143.40